logo-loader
IXICO PLC - IXICO draws 104% upside estimate from Cavendish as tools expand IXICO draws 104% upside estimate from Cavendish as tools expand

IXICO PLC (LSE:IXI, OTC:PHYOF) imaging platform upgrade and two technology partnerships support...

3 hours, 54 minutes ago
What Brokers Say

AstraZeneca gets Jefferies backing as broker sees $80bn sales target within...

AstraZeneca PLC (LSE:AZN, NYSE:AZN), the FTSE 100 pharmaceuticals group, has received fresh...

22 hours, 39 minutes ago
Deep Dive

Grey Matters Health is transforming Alzheimer’s diagnostics with a planned...

Drug repurposing model reduces risk and capital required Working to develop Ifenprodil for...

2 days, 20 hours ago
What Brokers Say

JP Morgan says GLP-1 costs may need to halve to unlock growth

JP Morgan sees meaningful but price-sensitive growth potential for GLP-1 medicines, with...

2 days, 23 hours ago

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

1 hour, 54 minutes ago

Join Proactive

Get ahead of the curve